Ocugen, Inc. (NasdaqCM: OCGN)
Health Care · Biotechnology · US
$1.39
+2.21% today · +30.8% 1Y
Ocugen, Inc. (NasdaqCM: OCGN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $461.19M and employs 116 people.
Over the last twelve months the share price has gained 30.8%, trading between 0.98 and 2.73.
Tweenvest scores Ocugen, Inc. across four factors: quality 19/100, value 51/100. Its strongest factor is value.
OCGN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $461.19M
- Revenue (TTM)
- $4.58M
- P/E
- —
- EPS
- -0.26
- Dividend yield
- —
- Beta (5Y)
- 2.20
- 52-week high
- $2.73
- 52-week low
- $0.98
- Avg volume (3M)
- —
- Shares outstanding
- 339.11M
- Employees
- 116
- Next earnings
- —
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
- ISIN
- US67577C1053
- Founded
- 2013
- Listed since
- Dec 3, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.04 | +0.57% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.17 | -0.15% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.75 | +1.37% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $553.44 | +1.07% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.58 | +0.61% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.90 | +14.41% |
Figures last refreshed Aug 18, 2026.